UPADACITINIB
upadacitinib 30 mg modified release tablet, 28
UPADACITINIB (13762H)
13762H
Manner of administration:Oral
Restriction
Indication: Severe Crohn disease
Treatment phase: Extended induction period (optional) from weeks 12 to 24
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 28 | # of repeats: 2 | DPMQ: $1,977.47 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Rinvoq | |||||